Clinical hurdles for curcumin and piperine nanoparticles in prostate cancer treatment: a bridge too far or a path to clinical reality?

While nano-encapsulation enhances the therapeutic index of curcumin, clinical translation remains stalled by a reliance on passive targeting and insufficient manufacturing scalability. Future success depends on shifting from 'beaker' synthesis to microfluidic production (Quality by Design) and adopting active targeting (e.g. PSMA-directed delivery) to penetrate the prostate stroma. Without these strategic pivots and biomarker-driven trials, CPNs risk remaining an academic curiosity rather than evolving into a viable clinical intervention.